Ranibizumab (Lucentis)
Definition / Overview
Ranibizumab is a humanized monoclonal antibody Fab fragment that binds all isoforms of VEGF-A. It was the first anti-VEGF agent specifically developed and approved for ophthalmic use. Smaller molecular weight than bevacizumab, theoretically allowing better retinal penetration.
Key Details
- Mechanism: Fab fragment binding all VEGF-A isoforms â inhibits vascular permeability and neovascularization
- Administration: intravitreal-injections, typically 0.5 mg/0.05 mL
- Molecular weight: ~48 kDa (Fab fragment â smaller than bevacizumab)
- Key trials: MARINA, ANCHOR, CATT â details to be added from dedicated sources
Clinical Relevance
Mentioned in the RAM context alongside bevacizumab as a treatment option for macroaneurysm-associated macular edema. Evidence is limited and primarily from case series.
Other major indications (to be expanded): wet AMD, DME, RVO-associated macular edema.
Associations
- bevacizumab â full-length parent antibody; lower cost alternative
- retinal-arterial-macroaneurysm â emerging treatment
- intravitreal-injections â delivery method
Sources
- macroaneurysm-eyewiki (brief mention only)
Gap: Needs dedicated sources on MARINA, ANCHOR, CATT comparison with bevacizumab, dosing protocols, and safety profile.